Reactive oxygen species as signaling molecules in the development of lung fibrosis
- PMID: 29080401
- PMCID: PMC5730357
- DOI: 10.1016/j.trsl.2017.09.005
Reactive oxygen species as signaling molecules in the development of lung fibrosis
Abstract
Pulmonary fibrosis is a relatively rare but devastating disease characterized by the excessive deposition of extracellular matrix. The increased matrix results in reduced lung compliance and increased work of breathing, while the obliteration of alveolar-capillary structures can result in hypoxemia and pulmonary hypertension, which manifests clinically as worsening shortness of breath, respiratory failure, and death. Unbiased genome-wide association studies combined with animal models suggest that damage to the alveolar epithelium is the initiating factor in pulmonary fibrosis. This epithelial injury leads to the activation and proliferation of myofibroblasts that secrete extracellular matrix proteins characteristic of fibrosis. The best described molecular link between alveolar epithelial dysfunction and myofibroblast activation and proliferation is the profibrotic cytokine transforming growth factor-β (TGF-β). We and others have found that mitochondrial and NAD(P)H oxidase-generated reactive oxygen species (ROS) play a signaling role to enhance TGF-β signaling and promote fibrosis. The purpose of this article is to review how ROS signaling leads to the activation of TGF-β. We suggest that an improved understanding of these pathways might explain the failure of nonselective antioxidants to improve outcomes in patients with pulmonary fibrosis and might identify novel targets for therapy.
Published by Elsevier Inc.
Figures

Similar articles
-
Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.Respir Res. 2017 Jun 2;18(1):114. doi: 10.1186/s12931-017-0600-3. Respir Res. 2017. PMID: 28577568 Free PMC article.
-
Oxidative Stress in Pulmonary Fibrosis.Compr Physiol. 2020 Mar 12;10(2):509-547. doi: 10.1002/cphy.c190017. Compr Physiol. 2020. PMID: 32163196 Review.
-
Reactive oxygen species modulator 1 regulates oxidative stress and induces renal and pulmonary fibrosis in a unilateral ureteral obstruction rat model and in HK‑2 cells.Mol Med Rep. 2017 Oct;16(4):4855-4862. doi: 10.3892/mmr.2017.7161. Epub 2017 Aug 3. Mol Med Rep. 2017. PMID: 28791399 Free PMC article.
-
SIRT3 blocks myofibroblast differentiation and pulmonary fibrosis by preventing mitochondrial DNA damage.Am J Physiol Lung Cell Mol Physiol. 2017 Jan 1;312(1):L68-L78. doi: 10.1152/ajplung.00188.2016. Epub 2016 Nov 4. Am J Physiol Lung Cell Mol Physiol. 2017. PMID: 27815257 Free PMC article.
-
The Role of Mitochondrial DNA in Mediating Alveolar Epithelial Cell Apoptosis and Pulmonary Fibrosis.Int J Mol Sci. 2015 Sep 7;16(9):21486-519. doi: 10.3390/ijms160921486. Int J Mol Sci. 2015. PMID: 26370974 Free PMC article. Review.
Cited by
-
NADPH oxidase 4 is protective and not fibrogenic in intestinal inflammation.Redox Biol. 2020 Oct;37:101752. doi: 10.1016/j.redox.2020.101752. Epub 2020 Oct 7. Redox Biol. 2020. PMID: 33059312 Free PMC article.
-
Vitamin A Deficiency and the Lung.Nutrients. 2018 Aug 21;10(9):1132. doi: 10.3390/nu10091132. Nutrients. 2018. PMID: 30134568 Free PMC article. Review.
-
Novel inhalation therapy in pulmonary fibrosis: principles, applications and prospects.J Nanobiotechnology. 2024 Mar 29;22(1):136. doi: 10.1186/s12951-024-02407-6. J Nanobiotechnology. 2024. PMID: 38553716 Free PMC article. Review.
-
Redox Balance Keepers and Possible Cell Functions Managed by Redox Homeostasis in Trypanosoma cruzi.Front Cell Infect Microbiol. 2019 Dec 20;9:435. doi: 10.3389/fcimb.2019.00435. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 31921709 Free PMC article. Review.
-
Helminth derived factors inhibit neutrophil extracellular trap formation and inflammation in bacterial peritonitis.Sci Rep. 2021 Jun 16;11(1):12718. doi: 10.1038/s41598-021-92001-9. Sci Rep. 2021. PMID: 34135384 Free PMC article.
References
-
- King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2014;370(22):2083–92. - PubMed
-
- Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2014;370(22):2071–82. - PubMed
-
- Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–7. - PubMed
-
- Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2006;174(7):810–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical